醒脑静联合尼莫地平治疗血管性痴呆临床疗效

To observe the clinical efficacy of Xingnaojing and nimodipine the treatment of vascular dementia

目的:研究醒脑静联合尼莫地平治疗血管性痴呆80例疗效及相关不良反应。方法:将我院住院的血管性痴呆患者80例,随机分为治疗组及对照组,两组各40例,两组患者入院后均给予调整血压,控制血糖,抗血小板、改善脑循环、应用脑保护剂等常规治疗;治疗组在此基础上加用尼莫地平,30 mg/次,3次/d;醒脑静注射液20ml加入生理盐水250 ml,静脉滴注,1次/d;两组患者疗程均为两周。两周后通过门诊或电话随访患者MMSE量表的积分,蒙特利尔认知评估量表(Mo CA),评定治疗前后的日常生活能力(ADL量表)。结果:治疗组的Mo CA,ADL评分明显优于对照组存在差异,且差异有统计学意义(P<0.05),并使以MMSE得分为标准的临床症状得到明显改善,其总有效率明显升高差异有统计学意义(82.5%VS67.5%,P<0.05)。结论:采用醒脑静注射液联合尼莫地平治疗血管性痴呆临床疗效好,能显著改善患者的认知功能和生活能力,且不良反应发生率低,安全性较高,故值得临床进一步推广使用。

Objective：To observe the clinical efficacy of Xingnaojing and nimodipine the treatment of vascular dementia.Methods 80 cases of vascular dementia patients were randomly divided into the treatment group and control group,each group 40 cases,two groups of patients after being hospitalized were given conventional treatment that is adjusting the blood pressure,controling blood sugar, improving cerebrocirculation,using brain protective agent and so on. The treatment group was given that nimodipine,30 mg per time,there times per day and Xingnaojing injection 20 ml adding the normal saline 250 ml intravenous drip,one per day,the course of treatment of two groups is tow weeks. Follow-up after tow weeks,through the outpatient or telephone,to observe the mini-mental state examination,Montreal Cognitive Assessment （MoCA） and activity of daily living.Results The results of MoCA,ADL is obviously better than that of the control group（P〈0.05）, the difference was statistically significant（P〈0.05）.the patient＇s clinical symptoms with MMSE as standard,is distinctly improved,The total effective rate significantly increased（82.5%vs 67.5%, P〈0.05）.Conclusion Xingnaojing injection joint nimodipine has positive effect on vascular dementia,can significantly improvethe cognition function and living ability;It s safe and reliable, So it is worth for clinical use.